Ziying Yi - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Ziying Yi

Showing results (21-30 of 23) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 23 results.

Nature Communications|September 1, 2025

AEBP1 drives fibroblast-mediated T cell dysfunction in tumorsXiaoyu Wang, Jie Li, Daqiang Song, et al.

Theranostics|July 14, 2022

FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblastsYushen Wu, Ziying Yi, Jie Li, et al.

The Journal of Clinical Investigation|November 15, 2024

Insulin-like growth factor 2 drives fibroblast-mediated tumor immunoevasion and confers resistance to immunotherapyDaqiang Song, Yushen Wu, Jie Li, et al.

Pageof 3

Search research articles

Showing results (21-30 of 23) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 23 results.

Nature Communications|September 1, 2025

AEBP1 drives fibroblast-mediated T cell dysfunction in tumorsXiaoyu Wang, Jie Li, Daqiang Song, et al.

Theranostics|July 14, 2022

FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblastsYushen Wu, Ziying Yi, Jie Li, et al.

The Journal of Clinical Investigation|November 15, 2024

Insulin-like growth factor 2 drives fibroblast-mediated tumor immunoevasion and confers resistance to immunotherapyDaqiang Song, Yushen Wu, Jie Li, et al.

Pageof 3